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Pneumococcus resists β-lactams by 
expressing variants of its target enzymes, the 
penicillin-binding proteins (PBPs), with many 
amino acid substitutions.  Up to 10% of the 
sequence can be modified.  These altered 
PBPs have a much reduced reactivity with the 
drugs but retain their physiological activity of 
cross-linking the peptidoglycan, the major 
constituent of the bacterial cell wall.  
However, as β-lactams are chemical and 
structural mimics of the natural substrate, 
resistance mediated by altered PBPs raises 
the following paradox: how PBPs that react 
poorly with the drugs maintain a sufficient 
level of activity with the physiological 
substrate?  This question is addressed for the 
first time in this study, which compares the 
peptidoglycan cross-linking activity of PBP2b 
from susceptible and resistant strains with 
their inhibition by different β-lactams.  
Unexpectedly, the enzymatic activity of the 
variants did not correlate with their antibiotic 
reactivity.  This finding indicates that some of 
the numerous amino acid substitutions were 
selected to restore a viable level of enzymatic 
activity by a compensatory molecular 
mechanism. 
Penicillin and other β-lactams are arguably 
the most important drugs ever, having had a 
global impact on human health in seven decades 
of continuous use to fend off bacterial infection 
(1).  β-Lactams hamper formation of the 
peptidoglycan, which is the main constituent of 
the bacterial cell wall.  Peptidoglycan is a giant 
polymer encasing the cell and consists of chains 
of tandemly repeated disaccharides cross-linked 
by peptide bridges.  This cross-linking results 
from a transpeptidation reaction catalysed by 
enzymes that are inhibited by β-lactams, which 
are mimics of the donor dipeptide of the 
transpeptidation reaction.  The enzymes 
responsible for the peptidoglycan assembly are 
called penicillin-binding proteins or PBPs2.  
They all have a penicillin-binding domain that 
generally catalyses the transpeptidation, but can 
also act as a carboxypeptidase or endopeptidase 
in some cases (2).  Some PBPs have an 
additional transglycosylase domain that catalyse 
the elongation of the glycan strands.  The bi-
functional transpeptidase and transglycosylase 
PBPs constitute the class A, whereas the mono-
functional transpeptidase PBPs are of class B. 
Resistance to antibiotics is recognized as a 
major threat to human health (3).  Resistance to 
β-lactams, which are the most widely used 
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antimicrobials, is particularly worrisome.  A 
case in point is that of pneumococcus, a major 
human pathogen that causes otitis, pneumonia 
and meningitis and is estimated to cause over 1.5 
million deaths per year (4).  Pneumococcus and 
related oral streptococci resists β-lactams by 
expression of altered PBPs (5) encoded by 
mosaic genes that result from multiple events of 
homologous recombination with genes from 
close species combined with additional point 
mutations (6).  A similar mechanism of β-lactam 
resistance operates in Neisseria species (7).  
Mosaic PBPs from resistant strains typically 
harbour tens of amino acid substitutions 
amounting to more than 10% of the primary 
sequence in some instances (5). 
Of the six PBPs in S. pneumoniae, three are 
commonly altered in β-lactam resistant strains: 
the two mono-functional transpeptidase PBP2b 
and PBP2x, and the bi-functional PBP1a (5).  
The mechanisms responsible for the diminution 
of the reactivity with the drugs have been 
investigated biochemically and structurally to 
various degrees for the three PBPs.  For PBPs 
from a β-lactam susceptible strain, the common 
source has been the laboratory strain R6, which 
has minimal inhibitory concentration (MICs) 
below 0.016 µg/mL for penicillin and 
cefotaxime.  The most thoroughly characterized 
PBPs from resistant pneumococcus are from the 
highly resistant strain 5204 isolated in France in 
1999, with MICs of 6 µg/mL for penicillin and 
12 µg/mL for cefotaxime (8). 
The mono-functional transpeptidase PBP2x 
is the most studied of these PBPs.  The role of 
important amino acid substitutions within the 
active site of PBP2x has been established by 
kinetics and structural studies.  For example, a 
mutation two residues downstream of the active 
site serine found in highly resistant strains was 
shown to change the orientation of the hydroxyl 
group of the serine, thereby diminishing its 
reactivity with β-lactams (9).  Two other 
substitutions common in resistant strains were 
shown to destabilize the structure of a loop that 
lines the active site (10).  A comprehensive 
study of all the substitutions in the 
transpeptidase domain of PBP2x from the highly 
resistant strain 5204 determined that only six of 
the 41 substitutions are important for reducing 
the reactivity with β-lactams (10). 
The other mono-functional class B PBP2b 
has not been as extensively studied, although the 
crystal structure has been solved for the variants 
from the susceptible laboratory strain R6 and the 
clinical resistant strain 5204 (11).  Like in 
PBP2x, a loop forming one side or “lip” of the 
active site is flexible in the variant from the 
resistant strain.  Sequence comparison identified 
the T446A substitution within the active site as 
critical for resistance, and an early biochemical 
study demonstrated that this mutation severely 
reduces the reactivity with β-lactams although 
no reaction kinetics could be measured (12).   
Likewise, the crystal structure of the 
transpeptidase domain of the class A  PBP1a 
was solved for the susceptible strain R6 and the 
resistant strain 5204 (13,14).  A mutation 
adjacent to the active-site serine was found to 
modify its orientation, and the loop forming a 
“lip” of the active site was destabilized as in 
PBP2x and PBP2b by a stretch of four 
substitutions (14). 
β-Lactams owe their tremendous medical 
success to their structural likeness to the terminal 
dipeptide dAla-dAla of the donor stem-peptide 
in the transpeptidation reaction (15).  The 
carbonyl of the β-lactam ring that is attacked by 
the nucleophilic active site serine is analogous to 
the carbonyl of the peptide bond that links the 
two terminal D-alanine residues of the 
peptidoglycan stem peptide.  Due to the 
similarity between the drugs and physiological 
substrate, we are facing the following paradox:  
PBP alterations that affect reaction with β-
lactams, as briefly presented above, would be 
expected to impact negatively on their 
transpeptidase enzymatic function.  To solve this 
paradox, compensatory mechanisms likely 
mitigate this problem.  Compensation could take 
place at the cellular level to cope with the 
effectively reduced enzymatic activity of the 
PBPs in resistant strains.  Alternatively, 
compensation could occur at the molecular level 
of the PBPs themselves if the consequences of 
some substitutions are different on the reactivity 
with the β-lactams and the transpeptidase 
activity.  The two types of compensatory 
mechanisms are not mutually exclusive and 
could operate together.   
Investigating cellular mechanisms that 
could compensate for lower PBP activity is very 
difficult as the cascade of events that occur in 
the pneumococcus following β-lactam challenge 
remains largely mysterious (e. g. (16-18)). 
Demonstrating the existence of 
compensatory mechanism to maintain the 
enzymatic activity of mosaic PBPs of S. 
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pneumoniae was not possible until recently as 
there was no assay to evaluate the transpeptidase 
activity in vitro.  This hurdle was removed since 
the proper peptidoglycan precursor is now 
available.  The nature of the stem penta-peptide 
of the membrane-linked precursor (lipid II) 
varies slightly in different bacterial species.  In 
the pneumococcus, the second residue is a γ-D-
iso-glutamine.  The discovery of the amido 
transferase enzyme (MurT/GatD) that modify 
the second residue γ-D-glutamate into γ-D-iso-
glutamine (19,20) has allowed the preparation of 
lipid II that can be used by pneumococcal PBPs 
to synthesize cross-linked peptidoglycan in vitro 
(21). 
To investigate the paradox raised by PBP-
based resistance and the structural similarity 
between β-lactams and the natural substrate of 
PBPs, we present here a comparison of four 
variants of PBP2b, (i) from the susceptible 
laboratory strain R6, (ii) from the clinical 
resistant strain 5204 (11,12), (iii) a hybrid form 
with the N-terminus from strain 5204 and the C-
terminus of strain R6, and (iv) the T446A point 
mutant (Figs 1 and 2).  5204-PBP2b carries 56 
substitutions, of which 43 are within the 
transpeptidase domain.  Hybrid-PBP2b carries 
28 substitutions including 15 in the 
transpeptidase domain and requires further 
presentation.  The hybrid form was not designed 
but results from the transformation of the R6 
strain with the pbp2b gene from strain 5204 and 
selection with piperacillin.  S. pneumoniae is 
naturally competent and readily recombine 
foreign homologous DNA.  An allele conferring 
a resistance can therefore easily be introduced 
and selected, provided flanking regions are 
provided to allow recombination.  With PBP2b, 
however, the whole gene could not be 
introduced as recombination repeatedly occurred 
within the coding region, resulting in a gene with 
the 5’-region from the resistant strain and the 3’-
region retained from the susceptible strain 
(12,18,22).  Characterization of the resulting 
Hybrid-PBP2B might shed light on this 
incomplete incorporation of the 5204-pbp2b 
allele in the R6 strain.  The T446A substitution, 
which is found in both 5204- and Hybrid-
PBP2b, is the most commonly found in resistant 
strains and can confer some resistance alone 
(12). 
For the first time, both the in vitro 
transpeptidase activity and the reactivity with a 
panel of β-lactams were evaluated for a set of 
PBPs.  We uncovered a new level of complexity 
as the impacts of substitutions on the 
transpeptidase activity and reactivity with β-
lactams are not fully correlated, revealing that 
some substitutions have compensatory effects 
that restore enzymatic activity.  We also 
discovered that variants of PBP2b can display β-
lactamase activity that may contribute to the 
resistance to some β-lactams. 
 
RESULTS 
Transpeptidase activity—To meaningfully 
compare their transpeptidase activity, it was 
necessary to use equivalent amounts of the 
PBP2b variants.  Impurities from the triton X-
100 and traces of oxidized DTT prevented the 
accurate determination of the concentrations of 
the detergent-solubilized full-length proteins 
from their UV absorbance.  Instead, protein 
amounts were determined in-gel after 
electrophoresis by quantifying the fluorescence 
of Bocillin-labeled PBP2b.  The truncated 
soluble forms of PBP2b were used as standards 
as their concentration could be determined from 
their UV absorbance.  Care was taken to use a 
concentration of Bocillin-FL and reaction time 
sufficient to completely label even the variants 
with lowest β-lactam reactivity.  That this was 
achieved was shown by the fact that the ratio of 
fluorescence to subsequent Coomassie-staining 
was similar for all proteins.  As Bocillin-binding 
implies a functional active-site, this observation 
suggests that the proportion of active enzyme 
was the same in all cases. 
Peptidoglycan assembly was monitored 
using the polyacrylamide gel electrophoretic 
assay used previously and presented by a scheme 
in Fig. 3 (21).  The lipid II peptidoglycan 
precursor migrates at the front, glycan chains of 
various length migrate as a smear within the gel, 
whereas high molecular mass cross-linked 
peptidoglycan, the product of transpeptidation, 
remains at the top of the gel.  A small amount of 
dansylated precursor (10%) is incorporated to 
allow in-gel fluorescence imaging under UV 
trans-illumination.  The amount of fluorescent 
precursor is kept to a minimum as it cannot 
function as acceptor in the transpeptidation since 
the dansyl group is attached to the lysine side 
chain that normally takes part in the reaction.  
PBP2b is a mono-functional transpeptidase that 
does not cross-link lipid II stem-peptides but 
requires polymerized glycan chains as substrate.  
Therefore, the S370A-PBP1a point mutant, 
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which is devoid of transpeptidase activity but 
retain a functional transglycosylase domain, was 
included to synthesize glycan chains from lipid 
II. 
The transpeptidase activity of the PBP2b 
variants was assessed by comparing the amount 
of fluorescence present at the top of the 
electrophoretic gel (Fig. 4).  In the end-point 
experiment shown in Fig. 4A, R6-PBP2b 
produced more cross-linked peptidoglycan after 
16 h of reaction than Hybrid-PBP2b, followed 
by 5204- and T446A-PBP2b.  The PBP2b 
variants were present in the same amount as 
checked by SDS-PAGE analysis of the protein 
mixtures after reaction with Bocillin and 
subsequent staining with Coomassie blue (Fig. 
4B).  Note that S370A-PBP1a did not react with 
Bocillin, as expected from the absence of the 
active-site serine. 
This crude assay does not measure the 
actual amount of peptide cross-links resulting 
from transpeptidation, but only the overall 
amount of cross-linked peptidoglycan.  
Nevertheless, assuming a uniform density of 
cross-links and considering the amount of cross-
linked peptidoglycan after 16 hours of reaction, 
the relative activity of the PBP2b variants can be 
ranked as follows:  R6 (100) > Hybrid (22 ± 3) > 
5204 (11 ± 2) > T446A (9 ± 2).  The numbers 
represent the amount of cross-linked 
peptidoglycan relative to that formed by R6-
PBP2b.  The error is the standard error to the 
mean of 5 independent experiments.  Although 
the difference between the amount of cross-
linked peptidoglycan produced by 5204- and 
T446A-PBP2b is small, the latter was smaller in 
all five experiments.  A one-tailed paired t-test 
of the data gave a p value of 0.035, indicating 
that the small difference is significant .  A time 
course is shown in Fig. 4C.  The transpeptidase 
activity of all PBP2b variants were inhibited 
with 1 mM penicillin G. 
The T446A mutant is the least active, 
despite having a single substitution that is also 
present in Hybrid- and 5204-PBP2b.  This 
observation implies that some of the 
substitutions found in the latter sequences are 
compensatory and increase the transpeptidase 
activity that is severely impacted by the T446A 
mutation.  Most interestingly, Hybrid-PBP2b, 
which is a laboratory selected chimeric 
sequence, has a better enzymatic activity than its 
parental clinical strain. 
 
Reaction with Bocillin FL, comparison 
between full length and soluble truncated 
PBP2bs—It is easier to produce and manipulate 
soluble proteins than detergent-solubilized 
membrane proteins.  As we aimed to 
characterize the acylation of PBP2b by several 
β-lactams, it was highly desirable to use a 
truncated soluble form of the proteins in the 
absence of detergent.  However, to ensure the 
relevance of such measurements, we first 
compared the reactivity of some detergent-
solubilized full length and soluble truncated 
PBP2bs with Bocillin FL monitored by 
polyacrylamide gel electrophoresis (Fig. 5). 
The reaction of PBPs with β-lactams can be 
described kinetically with the three step model 
(23) (Eq. 1).  A non-covalent complex PBP•βL 
is formed between the enzyme and the inhibitor 
(βL), with the dissociation constant KD, from 
which acylation proceeds to form the covalent 
complex PBP-βL with the rate k2.  PBP-βL is 
finally hydrolyzed with the rate k3 to regenerate 
the enzyme and an inactivated product P.  The 
rate described by k3 is usually negligible on the 
time scale of a bacterial generation.  The second 
order rate constant k2/KD is the efficiency of 
acylation, which allows calculation of the overall 
acylation rate at a given concentration of 
antibiotic.  Note that the inhibitory potency of a 
particular β-lactam for a PBP is given by the c50, 
which is the antibiotic concentration resulting in 
the inhibition of half the PBP molecules at 
steady state (i. e., when the acylation and 
deacylation reactions proceed at the same rate).  
The value of c50 is equal to the ratio k3/(k2/KD). 
 
KD  -1              k2                  k3
PBP + βL ⇄ PBP•βL → PBP-βL → PBP + P 
 
Eq. 1 
 
Purified recombinant PBP2b variants were 
incubated with various concentration of Bocillin 
FL (a fluorescently labeled penicillin V) in large 
excess.  After various time interval, aliquots 
were withdrawn and the reaction was stopped by 
the addition of a denaturing solution (0.2% SDS 
final) and heating at 100°C. Samples were 
analyzed by polyacrylamide gel electrophoresis 
which allowed the separation of PBP2b-bound 
Bocillin from the free form (Fig. 5A).  We 
checked that the inactivation procedure was 
effective by adding 1 mM Bocillin FL to the 
denaturing solution.  Minimal labeling of PBP2b 
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occurred in this way (sample Ctl, Fig. 5A).  The 
in-gel fluorescence of PBP2b-bound Bocillin 
was quantified and normalized with respect to 
the amount of PBP2b in each sample, as 
quantified after subsequent Coomassie staining.  
The second order rate constant k2/KD was 
obtained from global fitting of the time course 
data at the different drug concentrations using a 
second order reaction model described in Eq. 2 
(Fig. 5B).  With R6-PBP2b, which is highly 
reactive, using low drug concentrations in the 
same range as that of the protein was necessary 
to measure sufficiently slow reactions.  For this 
reason, we fitted the data without making the 
usual first-order approximation that is 
appropriate when the drug concentration is in 
large excess and can be considered constant. 
    k2 KD βL
PBP + βL        →       PBP-βL 
 
Eq. 2 
 
The acylation efficiency of R6-PBP2b by 
Bocillin FL was found in the range of 104 M-1s-1, 
which is similar to values reported with PBP3 
from Acinetobacter baumanii and Pseudomonas 
aeruginosa (24).  Reaction with 5204-PBP2b 
was about 200-fold slower, whereas it was 
reduced 1000-fold with Hybrid-PBP2b.  It is 
surprising that Hybrid-PBP2b is even less 
reactive with Bocillin than 5204-PBP2b, despite 
the fact that it exhibits a better transpeptidase 
activity. 
No difference of reactivity with Bocillin 
was found between the full-length and truncated 
proteins (Fig. 5C).  It was assumed to be true of 
all β-lactams and further kinetic data were 
obtained with the soluble forms only. 
 
Reaction with nitrocefin and competition 
with other β-lactams—In contrast to the other 
mono-functional PBP2x, the reaction of PBP2b 
with β-lactams has not been characterized in 
details, due to the absence of modification of the 
optical spectra upon acylation by the drugs (12).  
To palliate this lack of data, we measured the 
acylation efficiency by several β-lactams by 
monitoring the chromogenic reaction with 
nitrocefin.  The absorbance spectrum of 
nitrocefin changes upon opening of the β-lactam 
ring, and the reactions were followed by the rise 
in absorbance at 490 nm.  With nitrocefin alone, 
the data collected at different drug 
concentrations could be globally fitted to a 
second order reaction model to extract the 
acylation efficiency k2/KD (Eq. 3). 
     k2 KD NCF
PBP + NCF    →   PBP-NCF
 
 
Eq. 3 
 
With R6-, Hybrid- and T446A-PBP2b, no 
further degradation of nitrocefin was detected 
and reactions reached the expected 
stoichiometric plateau, unlike what had been 
observed in a study of Staphylococcus aureus 
PBP2a (25).  With 5204-PBP2b, a further linear 
increase of the absorbance was observed, which 
was interpreted as a hydrolysis turnover of 
nitrocefin.  Data could be fitted if the 
deacylation reaction (Eq. 4) was included in the 
model, which allowed to measure the constant 
k3. 
  k3 NCF
PBP-NCF         →       PBP + P1 
 
Eq. 4 
 
To obtain the acylation efficiency for other 
non-chromogenic β-lactams we performed 
competition experiments where each drug was 
added to PBP2b together with nitrocefin.  
Absorbance data, which measure the 
disappearance of nitrocefin, were fitted with a 
model that includes the two competing reactions 
described in Equations 2 and 3, while using the 
value of k2/KD for nitrocefin measured before.  
This was the case for R6- and T446A-PBP2b 
with amoxicillin, penicillin G, piperacillin and 
cefotaxime, as well as Hybrid-PBP2b with 
penicillin.  No reaction of 5204- and Hybrid-
PBP2b was observed with cefotaxime. 
Following the first phase of the reaction 
with 5204-PBP2, a linear increase of the 
absorbance was observed with amoxicillin, 
penicillin G and piperacillin, which was greater 
than with nitrocefin alone, indicating an 
additional hydrolysis turnover of these β-
lactams.  Data could be fitted with a model 
including the four reactions described in 
Equations 2 to 5, while introducing the k2/KD and 
k3 measured independently for nitrocefin. 
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 k3 βL
PBP-βL         →       PBP + P2 
 
Eq. 5 
 
In the cases of amoxicillin and piperacillin 
with Hybrid-PBP2b, a turnover of these 
antibiotics was also detected and the absorbance 
data were fitted with a model that included the 
three reactions described by Eqs 2, 3 and 5 
introducing the known k2/KD for nitrocefin. 
Examples of the data and regression curves 
are given in Fig. 6.  Note that in such 
competition assays between two reactants, of 
which only one can be monitored (such as 
nitrocefin in this case), the amplitude of the 
signal decreases and the apparent acylation rate 
increases with increasing concentrations of the 
invisible competitor (25).  Values of acylation 
efficiencies k2/KD, and deacylation rate constant 
k3 are given in Table 1.  Errors in Table 1 are 
standard errors from the regression, which do 
not include errors on the concentrations of drugs 
and proteins.  Concentration of the β-lactams 
was calculated from the weighted mass of 
powder used to prepare stock solutions.  Protein 
concentration was determined from the UV 
absorbance.  Assuming an error of 10% on the 
concentration of reactants, the accuracy of the 
measured acylation efficiencies is around 20%.  
With PBP2b, nitrocefin and Bocillin FL are the 
most reactive drug of our panel, followed by 
amoxicillin, piperacillin, and penicillin G.  
Cefotaxime is much less reactive.  R6-PBP2b 
has an efficiency of acylation by penicillin G of 
930 M-1s-1, which is 100-fold slower than the 
other mono-functional PBP2x (9).  With 
cefotaxime, R6-PBP2b is 4.107-fold less reactive 
than PBP2x (9).  Qualitatively, the reactivities 
measured in vitro here and in other studies for 
R6 PBPs (9,10,14) are in agreement with the 
acylations observed in vivo (18,26). 
The single T446A substitution accounts for 
most of the diminution in acylation efficiency 
with a 170- to 8-fold reduction with nitrocefin or 
piperacillin respectively.  The additional 55 
substitutions in 5204-PBP2b collectively only 
modestly affect the reactivity, whereas removal 
of the 27 C-terminal substitutions, as in Hybrid-
PBP2b, produces a further two-fold reduction 
(Table 1). 
 
Amoxicillin turnover evidenced by further 
reaction with Bocillin FL—Given the possible 
significance for resistance of the deacylation of 
5204-PBP2b with several β-lactams and the 
indirect way it was measured with nitocefin, we 
conducted an alternative time-course 
experiments with amoxicillin.  Full length R6- 
and 5204-PBP2b were first acylated by 
incubation with amoxicillin at a concentration 
sufficient to insure full acylation.  Then, at the 
start of the deacylation time course, an large 
excess of fluorescent Bocillin FL was added, at a 
concentration at which reaction can be 
considered instantaneous on the time scale of the 
experiment.  Amoxicillin was still present but its 
concentration much lower than that of Bocillin 
FL.  Reacylation by amoxicillin was therefore 
negligible and time course of labeling by 
Bocillin FL reflects the deacylation rate of the 
PBP2b-amoxicillin complex. 
A very slow deacylation of R6-PBP2b was 
detected.  After 80 min, less than 25% of the 
enzyme had been regenerated and able to react 
with Bocillin FL (Fig. 7A).  The data did not 
allow the determination of a reliable k3, but 
implied a value smaller than 6 10-5 s-1, or a half-
life of the acyl-enzyme greater than 3 h.  A 
comparable value of 3.8 10-5 s-1 has been 
reported for the deacylation of a radioactive 
penicillin G acyl-enzyme with a soluble form of 
R6-PBP2b (12).  Such rates are negligible on the 
bacterial generation time scale. 
In contrast, a significant deacylation was 
measured with 5204-PBP2b (Figs 7B and C).  
Nearly complete turnover was observed after 4 
min, which yielded the deacylation rate k3 = (10 
± 1) 10-3 s-1 and a half-life of the inhibitory 
complex of 70 s.  These values are clearly 
significant for growing bacteria.  The value of k3 
measured for full length 5204-PBP2b by the 
time course of reacylation with Bocillin FL is in 
good agreement with the value of 6.2 10-3 s-1 
measured by competition with nitrocefin for the 
soluble form of the protein (Table 1). 
 
Thermofluor assay—In order to gain 
insight on the interactions between the PBP2b 
variants and the various β-lactams that may 
account for the different kinetic behavior, we 
investigated the effect of the acylation on the 
thermal stability of the soluble proteins.  The 
thermofluor assay measure the fluorescence 
emitted by a probe (SYPRO® Orange) that 
binds to hydrophobic surfaces exposed during 
protein unfolding induced by rising the 
temperature (27,28).  Fluorescence of the probe 
is enhanced in the hydrophobic environment.  
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Thermofluor data without or with penicillin or 
piperacillin are shown in Fig. 8.  Three 
observations can be made from the melting 
temperatures (Tm) given in Table 2.  First, 
acylation of R6-PBP2b by penams such as 
amoxicillin, penicillin G and piperacillin 
stabilizes the protein, whereas acylation by the 
cephalosporin cefotaxime is destabilizing.  
Second, in the absence of bound antibiotic, R6-
PBP2b is thermally less stable than its variants 
from resistant strains. 5204- and Hybrid-PBP2b 
have the same higher Tm.  Third, on the contrary, 
variants from the resistant strains in their 
acylated form are more stable than acylated R6-
PBP2b.  This effect is more important for 5204- 
than for Hybrid-PBP2b.  Note that this does not 
apply with cefotaxime, which presumably did 
not acylate the resistance variants at the 
concentration used (1 mM). 
 
DISCUSSION 
The properties of the PBP2b variants 
measured in vitro, both the transpeptidase 
activity and the reactivity with β-lactams, are 
consistent with the impossibility to introduce the 
full PBP2b sequence from a clinical resistant 
strain (5204) into the susceptible strain R6.  
Indeed, the Hybrid-PBP2b resulting from the 
splicing of the N-terminal part of 5204-PBP2b 
and the C-terminal part of R6-PBP2b has better 
enzymatic activity and lower drug reactivity than 
the full 5204-PBP2b.  The biochemical 
properties of Hybrid-PBP2b explain why it is 
repeatedly selected by β-lactams in laboratory 
transformation experiments (12,18,22).  Note 
that if the c50 is considered, 5204-PBP2b is 
slightly less susceptible to β-lactam than Hybrid-
PBP2b.  The level of transpeptidase activity 
would therefore be the main factor favoring the 
selection of Hybrid-PBP2b instead of 5204-
PBP2b by β-lactams. 
Examination of the modeled structure of 
Hybrid-PBP2b shows that the missing 
substitutions compared to 5204-PBP2b are 
distributed in the “upper lip” of the active site 
and at the “back” of the protein (Fig. 2).  The 
“upper lip” substitutions A619G, D625G, 
Q628E and T630N are the most likely to cause 
the severe diminution of transpeptidase activity 
of 5204-PBP2b due to their proximity to the 
active site residues at the entrance of the cleft.  
The region spanning these substitutions forms a 
loop connecting strands β3 and β4 that is mobile 
and not visible in the crystal structure of 5204-
PBP2b (11).  However, the role of these 
substitutions in reducing the reactivity with the 
drugs is likely limited, contrary to what was 
thought previously (11), since Hybrid-PBP2b 
with a probable “stiff upper lip” is even less 
reactive with β-lactams than the more “relaxed” 
5204-PBP2b.  In contrast, substitutions in the 
“lower lip” of the active site S412P, N422Y, 
T426Q and Q427L likely contribute the most to 
the decrease in reactivity with the drugs.  
Interestingly and in agreement with the PBP2b 
observations, substitutions in the “lower” lip of 
PBP2x were found to reduce β-lactam reactivity, 
whereas substitutions in the β3-β4 “upper” lip 
had no effect or even increased the reactivity 
with the drug (10).  Note that the β3-β4 “upper” 
lip in PBP2x protrudes in the solvent and makes 
no contact with a bound cefuroxime molecule 
(29).  The “lower” lip on the contrary is held 
tightly against the active site and contacts the 
bound antibiotic.  Unfortunately, no crystal 
structure of PBP2b with bound antibiotic and no 
data on the transpeptidase activity of PBP2x 
variants are available to further compare both 
proteins. 
The deacylation rate (k3), which may also 
contribute to the resistance, is particularly 
elevated with 5204-PBP2b.  It is possible that 
the flexibility of the “upper lip” and the 
replacement of Ala619 by a glycine very close to 
the active site Ser386 allow easier access of 
water to the acyl-enzyme bond. 
The T446A substitution is the most 
important to reduce the acylation by β-lactams 
(Table 1).  Collectively, the 55 other 
substitutions in 5204-PBP2b cause only a 
modest additional reduction of the acylation rate 
(Table 1).  Among these, the 27 substitutions at 
the C-terminus must collectively have an 
opposite effect on the reactivity with β-lactams, 
since their absence in Hybrid-PBP2b further 
decreases the reactivity (Table 1).  The T446A 
mutation, however, is very detrimental to the 
transpeptidase activity, the point mutant being 
the less active of the four variants (Fig. 3). 
Therefore, among the many substitutions 
found in mosaic PBPs from resistant strains, 
some substitutions play key roles in reducing the 
reactivity towards β-lactams, such as the T446A 
in PBP2b or the six substitutions identified 
among 41 in the transpeptidase domain of 5204-
PBP2x (10)).  Other substitutions are likely 
neutral and present solely by virtue of the “hitch-
hiking” effect resulting from the homologous 
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recombination of long stretches of DNA.  What 
is revealed in the present study, is that some 
substitutions are compensatory and participate to 
the resistance not by restricting the reaction with 
the drugs, but by restoring an acceptable level of 
physiological enzymatic activity, that would 
otherwise be severely impacted by mutations 
that hamper the reaction with β-lactams. 
The findings above raise the question:  why 
is 5204-PBP2b present in a clinical resistant 
strain, since a sequence with fewer substitutions 
appears biochemically superior?  A clue can be 
found in a laboratory study of the transfer of β-
lactam resistance from Streptococcus mitis to S. 
pneumoniae (22).  The full sequence of PBP2b 
from a resistant S. mitis strain, including the 16 
substitutions at the C-terminus following 
position 590, could be transformed and selected 
by benzylpenicillin in S. pneumoniae, only if the 
mosaic variant of the murM gene from the S. 
mitis was also introduced. 
The murMN operon encodes two 
cytoplasmic enzymes responsible for the 
“branching” of the stem-peptides of the 
peptidoglycan (17).  The precursor of the 
peptidoglycan is synthesized with a 
pentapeptide, the third residue of which is a 
lysine in pneumococcus.  The free amine of the 
lysine side-chain of the donor peptide forms the 
peptide bond with the fourth residue (d-Ala) 
carboxyl group of the donor peptide to cross-link 
glycan chains.  Alternatively, MurM and MurN 
can add successively two residues onto the 
lysine side chain to produce “branched” stem-
peptides with additional Ser-Ala or Ala-Ala 
dipeptides.  It is then the N-terminus of the 
dipeptide on the acceptor that form the cross-
linking peptide bond with the donor stem-
peptide.  Strain R6 and its parental strain R36A 
were found to have about 45 and 36% 
“branched” peptides, respectively (30,31).  In 
clinical resistant strains that express a MurM 
variant from a mosaic allele, the proportion of 
“branched” stem-peptide is increased up to 85% 
(31), due to a greater enzymatic activity of the 
MurM variant (32).  In the absence of MurM, no 
“branched” peptides are detected, and the 
resistance is abolished despite the presence of 
altered PBPs (31). 
To explain the special relationship between 
PBP2b and MurM in β-lactam resistance, two 
plausible explanations can be considered.  More 
“branched” peptides may have a compensatory 
role (i) on the enzymatic activity of PBP2b or 
(ii) on the cell wall metabolism. 
(i) “Branched” stem-peptides may be better 
substrates for altered PBP2bs than the linear 
form, either as donor or acceptor, thus 
compensating the decreased transpeptidase 
activity.  It is highly desirable to test this 
hypothesis in vitro, but suitable substrates are 
unfortunately not available in sufficient 
amounts.  However, the fact that in the absence 
of antibiotic challenge, a strain devoid of MurM 
and “branched”-peptide grows normally with 
altered PBPs (31) argues strongly against PBP2b 
simply discriminating between different peptide 
substrates. 
(ii) PBP2b participates to the elongation of 
the ovoid pneumococcal cell (33).  Addition of 
peptidoglycan material to the cell wall during 
elongation requires concomitant opening of the 
existing peptidoglycan to permit insertion.  A 
peptidoglycan lytic transglycosylase has recently 
been identified that likely works in concert with 
PBP2b during elongation of the pneumococcus 
(34).  A decreased transpeptidase activity of 
PBP2b might create an imbalance with the 
degradative activity of its associated lytic 
transglycosylase that may trigger full lysis with 
the participation of other peptidoglycan 
hydrolases such as the major autolysin LytA.  
The greater proportion of “branched”-peptides 
due to mosaic MurM may protect against lysis.  
Indeed, elevated level of “branched”-peptides 
due to expression of a mosaic hyper-active 
MurM also protects against cell lysis normally 
induced by non-β-lactam antibiotics (17).  Also, 
gradual depletion of PBP2b was found to be 
tolerated to a large extent due to an increased 
level of “branched”-peptides.  In the absence of 
MurM, and consequently of “branched”-
peptides, depletion of PBP2b was much less 
tolerated (35). 
In conclusion, we propose that the 
deleterious effect of mutations that greatly 
diminish the reactivity of PBP2b with β-lactams, 
such as the T446A, is compensated by a 
combination of compensatory substitutions 
within PBP2b that maintain a minimal necessary 
transpeptidase activity, together with an 
alteration of the peptidoglycan composition that 
compensate for the reduced enzymatic activity. 
The reactivity with Bocillin FL of the 
extracellular domain of PBP2b was found to be 
the same as that of the full length membrane 
proteins (Fig. 5).  In contrast, the transpeptidase 
activity was severely impacted by the truncation 
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of the trans-membrane segment.  Residual 
activity was detected only with soluble R6-
PBP2b (not shown).  An influence of the 
membrane anchor on the active site cannot be 
ruled out, but is unlikely in the light of the 
reaction with β-lactams.  Rather, the glycan 
chains and the full length enzymes may be 
brought into close proximity by their common 
anchoring into detergent micelles.  This efficient 
concentration effect is lost by truncation of the 
trans-membrane segment.  In any case, the in 
vitro transpeptidase activities reported here and 
previously are extremely weak and far from 
realistic physiologic rates.  In the future, it will 
be necessary to study mono-functional PBPs in a 
membrane environment and/or in the presence of 
their protein partners (36), in particular SEDS 
proteins that act as transglycosylase (37). 
Additional comments can be made by 
comparing of the reaction rates with different β-
lactams.  Cefotaxime does not react significantly 
with PBP2b, as reported previously (12,26).  
This property is not general to cephalosporins, 
however, as nitrocefin was the most reactive 
drug of our panel.  Examination of the structure 
of the different cephalosporins that fail to react 
with PBP2b (26,38) suggests that the nature of 
the R2 substituent is important.  Bulky and 
planar substituent in position R2 appear to 
prevent recognition by PBP2b, whereas smaller 
and tetrahedral substituent seem compatible.  
The unfavorable interaction between cefotaxime 
and PBP2b seems to persist once the β-lactam 
ring is open and the acyl-enzyme complex is 
formed, as the thermal stability of the protein is 
diminished (Table 2). 
It is remarkable that substitutions that lead 
to the thermal stabilization of the apo-form of 
5204- and Hybrid-PBP2b compared to the apo-
form of R6-PBP2b, have the opposite effect on 
the acylated forms (Table 2).  In the variants 
from the resistant strains, the covalently bound 
drugs must make unfavorable interactions with 
the proteins.  Although the “open” forms of the 
antibiotics that are bound in the active site are 
different form the original β-lactams, they likely 
retain interactions that also occur in the pre-
acylation complex or the transition state, and 
may be relevant to the acylation and deacylation 
kinetics. 
Beside nitrocefin, which is not in clinical 
use, the most important diminution of reactivity 
measured for 5204-PBP2b compared to R6-
PBP2b was with amoxicillin.  It is also with 
amoxicillin that the greatest β-lactamase activity 
was measured for 5204-PBP2b (Table 1).  
Amoxicillin has long been a widely prescribed 
treatment for otitis media and sore throat, even 
when bacterial infection is not clearly diagnosed 
(39,40).  The nasopharyngeal flora, including S. 
pneumoniae has therefore been subjected to a 
severe selection pressure by amoxicillin and it is 
possible that the substitutions found in 5204-
PBP2b reflects the clinical practice.  Strain 5204 
exhibits the highest level of amoxicillin 
resistance (MIC 6 µg mL-1) in a panel of French 
clinical isolates, together with isolate 5268, 
which has a similar PBP2b sequence (8). 
The surprising finding that a laboratory 
selected PBP2b (Hybrid) performs better in vitro 
than its clinical parental variant (5204) indicates 
that β-lactam resistance in pneumococcus is a 
complex process that is not fully described by 
biochemical reconstitution experiments.  
Resistance to β-lactams must be considered as a 
complete physiological response with 
compensatory mechanisms at play.  Such 
mechanisms should be studied in the future as 
they that may offer novel therapeutic options. 
 
 
EXPERIMENTAL PROCEDURES 
Chemicals—Lyophilized nitrocefin was 
purchased from Oxoid (ref: SR0112C) and 
reconstituted at 2 mM in DMSO and stored at -
20°C.  Bocillin FL was from ThermoFischer 
Scientific (ref: B13233).  Stock solutions were 
prepared in 50 mM HEPES, pH 7.5, 100 mM 
NaCl, 10 mM MgCl2 at 50mM and stored at -
20°C.  Amoxicillin (ref: A8523), cefotaxime 
(ref: C7912), penicillin G (ref: P3032) and 
piperacillin (ref: P8396) were from Sigma and 
solubilized at 100 mM in the same buffer and 
stored at -20°C, except amoxicillin, which was 
solubilized with the addition of 1% NH4OH and 
kept for a maximum of 15 days at -80°C. 
Lys-containing lipid II and dansylated 
lipid II were prepared as described previously 
(41,42).  Amidation of lipid II and subsequent 
purification were performed as previously (21). 
 
Structure modeling—The structural model 
of Hybrid-PBP2b was constructed by 
superposing the crystal structures of R6-PBP2b 
(PDB# 2WAF) from residue 518 to 682 onto 
that of 5204-PBP2b (PBD# 2WAD) using LSQ 
Superpose in COOT (43) from the CCP4 
program suite (44).  The model structure was 
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then created by replacing residues 518-682 in 
5204-PBP2b by those from R6-PBP2b.  As 
examination of the model found no clash or 
other anomaly, a simple structure idealization 
was performed with REFMAC (45). 
 
Expression plasmids—Full-length R6-
PBP2b with a C-terminal Strep-tag was 
expressed from the modified pET-30 plasmid 
described before (21).  The gene encoding 
Hybrid-PBP2b was PCR amplified from 
genomic DNA from laboratory strain R6 ΔlytA 
pbp2b5 (18) using primers Nde2b and 
2bStopNheSpeBam (21).  The gene coding for 
5204-PBP2b was amplified from DNA of the 
clinical strain 5204 (8) using primers Nde2b and 
2b5204Bam (GGTCGACGGATCCATTCATTG 
GATGGTGTTGG).  A NdeI internal site was 
silently mutated by PCR using primers 
2b5204mutNdeFW (GTATAAATTGGCGTAT 
GGATCTTTTC) and 2b5204mutNdeRV (GA 
AAAGATCCATACGCCAATTTATAC).  The 
resulting PBP2b coding genes were introduced 
as NdeI/BamHI fragments into a modified pET-
30 plasmid, which encodes a C-terminal Strep-
tag. 
N-terminally truncated versions of the 
three PBP2b variants starting at residue M39 
were sub-cloned in the same modified pET-30 
expression plasmid following PCR amplification 
from the parent plasmids encoding the full-
length proteins, using primers Nde2bstar 
(GAGAATTCCATATGCAGGTTTTGAACAA
GGATTTTTACG) and 2bStopNheSpeBam or 
2b5204bam.  All final coding sequences were 
checked. 
 
Protein expression and purification—Full-
length S370A-PBP1a with an N-terminal His-tag 
was produced and purified as described (46). 
The preparation of PBP2bs were as 
detailed in the supporting information of 
previous work (21).  Briefly, all pneumococcal 
proteins were produced in Escherichia coli 
BL21 (DE3) star.  Full-length variants were 
purified from Triton X-100 solubilized 
membranes whereas soluble truncated forms 
were purified from the soluble fraction of cell 
lysates.  All variants harboring a C-terminal 
Strep-tag were purified by Strep-Tactin affinity 
affinity chromatography in 50 mM HEPES, pH 
7.5, 150 mM NaCl, 10 mM MgCl2.  Proteins 
were eluted with 2.5 mM desthiobiotin.  Full-
length protein solutions also contained 0.02% 
Triton X-100 and 1 mM DTT as the PBP2bs 
contain a cysteine residue near the N-terminus. 
 
Peptidoglycan synthesis—Unlabelled iso-
glutamine-containing lipid II and dansylated 
lipid II in CHCl3:methanol (1:1) were mixed in a 
10:1 ratio and dried under nitrogen flow. The 
dried lipid II mix was then redissolved to a final 
concentration of 55 µM in the reaction mix 
typically containing 50 mM HEPES, pH 7.5, 150 
mM NaCl, 10 mM MgCl2, 25% (v/v) DMSO, 
and 0.02% (w/v) Triton X-100, and the PBPs 
investigated.  The concentrations of buffer, salts, 
and particularly of detergent contributed by the 
protein stocks were taken into account.  The 
concentration of S370A-PBP1a and PBP2bs 
were 0.3 and 1 µM, respectively.  Penicillin G (1 
mM) was included as required.  Reactions were 
left to proceed overnight at 30 °C unless 
otherwise stated.  For time course experiments, 
aliquots were withdrawn after various time 
intervals, and the reaction was stopped by the 
addition of penicillin G (1 mM) and 
moenomycin (Flavomycin, Hoechst, 0.5 mM).  
Samples were analysed by SDS-PAGE (21) and 
visualized with blue trans-illumination using the 
GelDoc ChemiDoc MP imager (BioRad).  
Quantification was performed on unsaturated 
images using the Image Lab software (BioRad). 
 
Kinetics of PBP2b reaction with Bocillin 
FL—Full-length and truncated soluble variants 
of PBP2b were incubated in the presence of 
various concentrations of Bocillin FL at 20°C in 
50 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM 
MgCl2, and 0.02% (w/v) Triton X-100 for the 
full length proteins.  The ranges of Bocillin FL 
concentrations were from 5 to 20 µM for R6-
PBP2bs or 0.25 to 1 mM for Hybrid- and 5204-
PBP2bs.  Aliquots were withdrawn after various 
time intervals, and the reaction was stopped by 
the addition of loading buffer (0.2% (w/v) SDS 
final concentration) and a heat shock (100°C, 5 
min).  The fluorescence of Bocillin-PBP2b 
complexes was recorded under blue trans-
illumination.  Fluorescence data were corrected 
for the relative amount of PBP2b in each sample 
after subsequent quantification of Coomassie-
stained protein bands.  Imaging and 
quantification were performed using a GelDoc 
ChemiDoc MP imager and the Image Lab 
software (BioRad).  Data were fitted globally 
with the DynaFit software (47) (Biokine) using a 
second order reaction model. 
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Amoxicillin deacylation kinetics—Full-
length R6- or 5204-PBP2b were incubated at 1 
µM for 15 min at 20°C with 100 µM amoxicillin 
in 50 mM HEPES, pH 7.5, 150 mM NaCl, 10 
mM MgCl2, and 0.02% (w/v) Triton X-100, 
prior to addition of 1 mM Bocillin FL at time 
zero of the deacylation time course.  After 
various time intervals, the reaction was stopped 
and samples were analyzed as above.  Data for 
the fraction (f) of Bocillin-labeled protein were 
fitted to a first-order kinetic (f = 1-exp(-k3t)) 
using the Kaleidagraph software (Synergy). 
 
Kinetics of PBP2b reaction with nitrocefin 
and other β-lactams—The different soluble 
PBP2b variants were incubated with either 
various concentrations of nitrocefin, or a fixed 
concentration nitrocefin and varying 
concentrations of other β-lactams, in 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 10 mM MgCl2.  
Absorbance at 490 nm was recorded at 25°C in 
an OPTIMA FLUOstar plate reader where 150 
µL of protein solution were automatically 
injected onto 100 µL of antibiotic solution in a 
Greiner 96-wells plate.  PBP2b and drug 
concentrations were as follows.  With 18 µM 
R6-PBP2b, nitrocefin was varied alone from 20 
to 100 µM, whereas it was kept at 10 µM while 
amoxicillin ranged from 0 to 25 µM, penicillin 
G from 0 to 800 µM, piperacillin from 0 to 80 
µM and cefotaxime from 0 to 5 mM.  With 20 
µM 5204-PBP2b, nitrocefin was varied alone 
from 100 to 500 µM, whereas it was kept at 150 
µM while amoxicillin and penicillin G ranged 
from 0 to 2.5 mM,  and piperacillin from 0 to 
800 µM.  With 30 µM Hybrid-PBP2b, nitrocefin 
was varied alone from 200 to 800 µM, whereas 
it was kept at 70 µM while amoxicillin ranged 
from 0 to 1.2 mM,  penicillin G from 0 to 2 mM 
and piperacillin from 0 to 150 µM.  With 20 µM 
T446A-PBP2b, nitrocefin was varied alone from 
70 to 200 µM, whereas it was kept at 35 µM 
while amoxicillin ranged from 0 to 625 µM, 
 penicillin G from 0 to 2.4 mM, piperacillin from 
0 to 300 µM, and cefotaxime from 0 to 4.5 mM. 
For each PBP2b variant, the data for a 
range of β-lactam concentrations were fitted 
globally with the DynaFit software (47) 
(Biokine) using second order reaction models for 
the acylations and first order model for the 
deacylation, as described in the Results section. 
 
Thermofluor assay—Soluble PBP2b 
variants at a final concentration of 0.5 mg/mL 
(about 6 µM) were incubated with or without 1 
mM of amoxicillin, penicillin G, piperacillin or 
cefotaxime, in 50 mM HEPES, pH 7.5, 150 mM 
NaCl, 10 mM MgCl2 for 5 min at room 
temperature prior to addition of SYPRO® 
Orange (12x final) on ice.  Fluorescence melting 
curves were recorded in the SYBR channel in a 
CFX Connect instrument (Biorad) with a 20 to 
100°C temperature ramp (0.5°C steps of 7.2 s) 
and analyzed with the CFX Manager software. 
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FIGURE LEGENDS 
FIGURE 1.  Sequence alignment of PBP2b variants.  The yellow band indicate the extent of the 
transpeptidase domain.  The scissors indicate the site of truncation to produce the soluble extracellular 
domain.  Conserved active site motifs are denoted by asterisks and corresponding residues are boxed 
in red, or green for the active site serine that undergoes acylation.  Other boxed residues indicate 
positions that are substituted in 5204-PBP2b.  The important T446A mutation is in orange and 
denoted by a triangle.  The sequence from 5204-PBP2b is in grey, that of R6-PBP2b is in blue.  The 
sequence of hybrid-PBP2b is colored according to its two sequences of origin, with the junction 
positioned arbitrarily midway between unambiguous positions.  Residues forming the “upper lip” of 
the active site (619-629) are in a darker shade. 
 
FIGURE 2.  Structural model of the extracellular domain of Hybrid-PBP2b.  The model was 
constructed by combining the x-ray structures of R6- and 5204-PBP2b (PDB entries 2WAF and 
2WAD).  The positions of the active site residues and substitutions are shown by spheres.  The color 
scheme is as in Fig. 1.  Therefore, the substitutions shown in blue are present in 5204-PBP2b and 
absent in Hybrid-PBP2b. 
 
FIGURE 3.  Scheme of the in vitro reaction of peptidoglycan synthesis performed and the gel 
system used for analysis.  Transpeptidase inactivated S370A-PBP1a was used to elongate glycan 
chains by transglycosylation (TG) and PBP2b cross-linked chains by transpeptidation (TP).  A small 
amount of fluorescent lipid II (denoted by a star) was incorporated to visualize the reagents and 
products after polyacrylamide gel electrophoresis. 
 
FIGURE 4.  In vitro transpeptidase activity of PBP2b variants.  Reactions were carried out with 
0.3 µM S370A-PBP1a to polymerize the glycan chains, without (Ctl) or with 1 µM of the different 
PBP2b variants, at pH 7.5, 30°C and the presence of 0.02% Triton X-100, with 50 µM lipid II and 5 
µM dansylated lipid II.  The assay is depicted schematically in Fig. 3.  (A) SDS-PAGE analysis of 
peptidoglycan synthesis after overnight reaction.  (B) SDS-PAGE analysis of the protein mixes used 
in (A) after reaction with Bocillin.  The PBP2b-bound Bocillin was revealed by UV trans-illumination 
(bottom panel), prior to Coomassie staining (top panel).  (C) Time course of peptidoglycan synthesis 
reactions.  Reactions were stopped after various time interval by the addition of penicillin and 
moenomycin.  The graph shows the quantification of the cross-linked peptidoglycan resulting from 
R6- (●), Hybrid- (■), 5204- (▴), and T446A-PBP2b (◆) activity, as the fraction of fluorescent material 
remaining at the top of the gel, after subtraction of the amount measured in the control in the absence 
of PBP2b (Ctl). 
 
FIGURE 5.  Reaction of full-length and soluble PBP2b variants with Bocillin FL at pH 7.5 and 
25°C.  (A) Time course of the reaction of 1 µM Hybrid-PBP2b with 1 mM of Bocillin FL.  The 
reaction was stopped after various time intervals by the addition of SDS-containing loading buffer and 
analyzed by SDS-PAGE.  Ctl is the control of PBP2b inactivation by SDS where 1mM of Bocillin FL 
was added to the loading buffer. BCN indicates the fluorescence of Bocillin FL and CB the 
Coomassie-stained protein.  (B)  Time course of the reaction of 1 µM R6-PBP2b with 5 (◆), 10 (▴), 
15 (■) and 20 µM (●) of Bocillin FL.  The procedure was as in (A).  The fluorescence of Bocillin FL 
weighted by the Coomassie protein signal of each sample was plotted versus time.  The regression 
curves were calculated globally using a second order reaction model.  (C)  Comparison of the 
acylation efficiencies of full length and soluble truncated forms of PBP2b, measured as in (A) and (B).  
Error bars are the standard errors from the regressions. 	  
 at U
niversity of W
arw
ick on February 2, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Transpeptidase activity and β-lactam reactivity of pneumococcal PBP2b	
16	
FIGURE 6.  Reaction of soluble PBP2b variants with nitrocefin, alone or in competition with 
amoxicillin, at pH 7.5 and 25 °C.  The change in absorbance that occurs upon opening of the β-
lactam ring of nitrocefin was recorded at 490 nm.  A fraction of the data points is shown (between 5 
and 20%).  The solid lines are global fits to the data using the reaction models described in the text.  
Rate constants are given in Table 1.  (A) 18 µM of R6-PBP2b was incubated in the presence of 20 (●), 
40 (■), 60 (▴), 80 (◆) and 100 (▼) µM of nitrocefin.  (B) 20 µM of T446A-PBP2b was incubated in 
the presence of 35 (●), 50 (■), 70 (▴), 85 (◆) and 100 (▼) µM of nitrocefin.  (C) 30 µM of Hybrid-
PBP2b and 70 µM of nitrocefin were incubated in the presence of 0 (▼), 150 (◆), 300 (▴), 600 (■) and 
1200 (●) µM of amoxicillin.  (D) 20 µM of 5204-PBP2b and 50 µM of nitrocefin were incubated with 
of  0 (▼), 75 (◆), 150 (▴), 300 (■) and 600 (●) µM of amoxicillin. 
 
FIGURE 7.  Deacylation of the PBP2b-amoxicillin complex.  Full-length R6- (A) and 5204-PBP2b 
(B) were incubated at 1 µM for 15 min with 100 µM amoxicillin prior to the addition at time zero of 
1 mM of Bocillin FL.  After various time intervals, the reaction was stopped by the addition of 
denaturing loading buffer and samples were analyzed by SDS-PAGE.  Fully Bocillin-labeled samples 
were prepared without amoxicillin (Ctl).  Bocillin-labeled PBP2b was imaged and quantified under 
UV illumination.  (C) Data for the labeling of 5204-PBP2B were fitted to a first-order kinetic to 
extract the amoxicillin deacylation constant k3 = (10 ± 1) 10-3 s-1.  The error is the standard error from 
the regression. 
 
FIGURE 8.  Thermal denaturation of PBP2b variants in apo and acylated forms (Thermofluor).  
Soluble truncated R6- (A), Hybrid- (B) and 5204-PBP2b (C) were incubated without (continuous line) 
or with 1 mM penicillin (wide-dashed line) or piperacillin (short-dashed line) prior to thermal 
denaturation in the presence of the fluorescent probe SYPRO® Orange.  The first derivative of the 
fluorescence as a function of increasing temperature is shown. 
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TABLE 1 
Kinetic parameters of the reaction between β-lactams and PBP2 variants 
NCF, AMX, PEN, PIP and CTX results are from a continuous colorimetric assay following 
absorbance increase at 490 nm resulting from the reaction of nitrocefin.  BCN results are from SDS-
PAGE time course expriments.  Errors are the standard errors from the regressions. 
 
  R6 T446A 5204 Hybrid 
NCF 
k2/KD (M-1s-1) 12700 ± 350 74 ± 13 230 ± 2 120 ± 6 
k3 (s-1) ND ND (8 ± 2) 10-5 ND 
c50 (M)   3.5 10-7  
AMX 
k2/KD (M-1s-1) 3000 ± 130 222 ± 10 70 ± 2 40 ± 1 
k3 (s-1) ND ND (6.2 ± 0.1) 10-3 (1.0 ± 0.2) 10-4 
c50 (M)   8.9 10-5 2.5 10-5 
PEN 
k2/KD (M-1s-1) 930 ± 25 33 ± 1 35 ± 1 19 ± 0.3 
k3 (s-1) ND ND (2.0 ± 0.05) 10-3 ND 
c50 (M)   5.7 10-5  
PIP 
k2/KD (M-1s-1) 2400 ± 94 280 ± 8 190 ± 6 80 ± 2 
k3 (s-1) ND ND (4.0 ± 0.2) 10-4 (7 ± 2) 10-5 
c50 (M)   2.1 10-6 9 10-7 
CTX 
k2/KD (M-1s-1) (5 ± 2) 10-3 (1.0 ± 0.1) 10-3 < 10-3 < 10-3 
k3 (s-1) ND ND ND ND 
BCN k2/KD (M-1s-1) 13700 ± 111 ND 68 ± 11 12 ± 1 
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TABLE 2 
Melting temperatures (Tm) of PBP2b in the absence or presence of 1 mM β-lactam 
Tm (°C) were determined as the minimum of the first derivative of the melting curves.  The mean of 
two experiments is given.  Standard deviation was at most 0.5°C. 
 
 none AMX PEN PIP CTX 
R6-PBP2b 49.5 59.0 57.5 59.5 46.0 
5204-PBP2b 52.0 53.0 45.5 51.5 52.0 
Hybrid-PBP2b 52.0 56.0 49.0 54.5 52.5 
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